Large-scale data analyses enabled by Numatix, Numerate's distributed framework

SAN BRUNO, Calif., July 10 — Numerate, Inc., a technology platform company that is leveraging proprietary algorithms and the power of cloud computing to transform the drug design process, announced today that its drug discovery platform, based on its open-source distributed framework, Numatix, has been shown to reliably and cost-effectively scale to 10,000+ cores using spot instances on Amazon Web Services' Elastic Cloud Compute (AWS EC2). The 10,000+ cores were used to screen virtual compounds against predictive assay models in one of the company's commercial partnerships.

Numatix is a dataflow processing platform developed by Numerate that enables great scalability and flexibility in distributed computing with minimal operational overhead. Combining online processing with detailed dataflows, Numatix allows for the deep and interactive analyses of large data sets. At Numerate, Numatix is used for the computational assessment of billions of molecules in the search for new drugs and for the development of complex systems biology models of drug behavior in various animals and humans.

"This level of scalability is essential for Numerate due to growing demand for our drug design services in the pharmaceutical and biotechnology industry," said Nigel Duffy, Ph.D., chief technology officer. "This achievement demonstrates the power of the Numatix platform and its ability to tackle large-scale computational problems cost effectively. We designed Numatix from the ground up to be extremely robust to all types of failures, allowing us to take full advantage of spot instances and their cost savings."

"We were able to scale up to 10,000 nodes in the US-East zone of EC2," stated Brandon Allgood, Ph.D., Director of Computational Science. "And because the Numatix platform uses spot instances, the cost was only 2.7¢ per core-hour, or $270 per hour for a 10,000-core cluster – just one-third of the on-demand cost. Moreover, we were able to reach this scale while handling spot instance ephemeralness and maintaining a high level of security."

Allgood added, "The limiting factor on this run was our cloud provider-independent security layer. On less sensitive types of workloads, we expect that Numatix should be able to scale well beyond 10,000 cores."

Numerate is currently making Numatix available to a broad range of users in the life sciences. Future applications in other fields, such as finance, manufacturing and energy, can be envisioned. For more information, please visit www.numatix.net or contact info@numatix.net or follow us on Twitter @numatixData.

About Numerate

Numerate is a privately held biotechnology company pioneering new computational methods for making the drug design process more data-driven, efficient and predictable. Numerate's in silico drug design platform combines proprietary algorithms and cloud computing with traditional medicinal chemistry approaches to address, in parallel, the factors that determine the success and failure of a drug candidate. Numerate applies this proprietary platform to design and develop small molecule therapeutics in collaboration with a variety of partners in the pharmaceutical, biotechnology, and academic fields. For more information, please visit www.numerate.com (corporate site) and www.numerati.com (technical site).

-----

Source: Numerate, Inc.